Hybrigenics announced the elections of Dr. Alain Munoz as chairman of its board and of Mr. Mogens Vang Rasmussen as an independent director. Dr. Munoz joined Hybrigenics' board in 2011 as a director especially in charge of clinical development (cf. Hybrigenics' press release of October 05, 2011).

Now that inecalcitol enters a phase of clinical development both in Europe and the USA, Dr. Munoz replaces as Chairman Mr. Daan Ellens, who was not candidate for re-election after ten years of chairmanship. Mr. Vang Rasmussen started his career at Novo Nordisk in 1983 and held several positions in corporate controlling and investor relationships, first at the Danish headquarters and later in New-York for all North-American activities. In 1994, he joined Tele Danmark (now TDC) as vice- president, senior economist.

In 1999, he moved to MediCult as CFO and was promoted CEO. From 2003 to 2010, Mr. Vang Rasmussen has worked at Zealand Pharma where he last was both CFO and COO. In 2010, he set up his firm, Ibenfeldt Consulting, and completed various long term transition CFO missions such as at Serodus A/S and Urodan ApS.

Mr. Vang Rasmussen is a partner of Vesicon SAS in France and Chairman of the Board of Pila Pharma AB in Sweden.